Stage 1 multiple myeloma features low beta-2 microglobulin, high albumin, and no organ damage, often detected incidentally. Diagnosis involves blood, urine, imaging tests, and bone marrow biopsy to ...

Lynozyfic (linvoseltamab-gcpt) is a prescription injection medicine for people with a type of blood cancer called multiple myeloma, whose cancer has come back (relapsed) or worsened (refractory) after ...

Kyprolis is a type of medicine called a proteasome inhibitor. The proteasome is like the cell's "trash disposal" system. Proteasome inhibitors such as Kyprolis bind to and block the activity of the ...

Common manifestations and complications of multiple myeloma (MM) can include bone complications, hypercalcemia, renal insufficiency, infection, skeletal lesions and anemia. Other less common ...

Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive CAR T cell therapy for multiple myeloma share a common immune root cause, ...

Immunotherapy is a type of cancer treatment that uses the power of a person’s immune system to fight their cancer. Instead of directly attacking cancer cells like chemotherapy or radiation, ...

A blood and marrow transplant (BMT) is a treatment used for certain cancer types that works by resetting the body’s ability to make healthy blood cells. It does this by replacing damaged or destroyed ...

Ameet Patel, MD, explains how multiple myeloma treatment settings depend on safety, logistics, and patient needs.

Building on bispecific antibodies, four of which have been approved by the FDA to treat relapsed/refractory multiple myeloma, next-generation trispecific antibodies are yielding high response rates in ...

This is a great question. So I personally think that CAR T-cell therapies, they do have a meaningful positive impact on quality of life for many myeloma patients, particularly after recovery from the ...

Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

Doctors at Boston’s Beth Israel share how CAR T cell therapy and other emerging immune therapies are delivering promising ...